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Abstract: The aetiology of Kawasaki disease (KD), an acute inflammatory disorder of childhood,
remains unknown despite various triggers of KD having been proposed. Host ‘omic profiles offer
insights into the host response to infection and inflammation, with the interrogation of multiple
‘omic levels in parallel providing a more comprehensive picture. We used differential abundance
analysis, pathway analysis, clustering, and classification techniques to explore whether the host
response in KD is more similar to the response to bacterial or viral infections at the transcriptomic and
proteomic levels through comparison of ‘omic profiles from children with KD to those with bacterial
and viral infections. Pathways activated in patients with KD included those involved in anti-viral and
anti-bacterial responses. Unsupervised clustering showed that the majority of KD patients clustered
with bacterial patients on both ‘omic levels, whilst application of diagnostic signatures specific for
bacterial and viral infections revealed that many transcriptomic KD samples had low probabilities
of having bacterial or viral infections, suggesting that KD may be triggered by a different process
not typical of either common bacterial or viral infections. Clustering based on the transcriptomic
and proteomic responses during KD revealed three clusters of KD patients on both ‘omic levels,
suggesting heterogeneity within the inflammatory response during KD. The observed heterogeneity
may reflect differences in the host response to a common trigger, or variation dependent on different
triggers of the condition.
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1. Introduction
Kawasaki disease (KD) is an acute inflammatory disorder first described in Japan
over 50 years ago [1]. KD occurs most frequently in children under five years of age [2].
Untreated KD leads to the formation of coronary artery aneurysms (CAAs) in 10–30% of
children [3–5], making it the most common cause of acquired heart disease in children in
Europe, Japan and North America [6].
The aetiology of KD remains unknown. However, the seasonality and epidemicity
seen in areas of high incidence, including Japan, suggest that it is caused by an infectious
trigger [7]. The current consensus is that, in some genetically predisposed children, an
infectious trigger initiates an abnormal immune response [8,9]. Multiple viral and bacterial
pathogens have been suggested as candidates for the trigger, in addition to airborne
environmental and fungal triggers [8,10]. Despite the many theories postulated, none have
been independently confirmed, and some studies have concluded that KD is likely to be
caused by multiple environmental triggers [11].
As the coronavirus disease 2019 (COVID-19) pandemic evolved in early to mid-2020,
an increase in cases of children with unusual febrile illnesses, some with features resem-
bling KD, was observed [12]. This new condition, which was later termed “Paediatric
Inflammatory Multisystem Syndrome Temporally associated with SARS-CoV-2”, or “Mul-
tisystem Inflammatory Syndrome in Children” (PIMS-TS or MIS-C) [12–15], tends to arise
several weeks after SARS-CoV-2 infection [14]. The finding of increased KD-like cases
after the emergence of a novel viral pathogen raises questions about whether more than
one type of trigger might cause KD, and whether KD might represent a constellation of
overlapping inflammatory syndromes.
Study of host transcriptomic and proteomic profiles can reveal perturbations caused by
infection or inflammation. Comparison of the transcriptional response in different diseases
has revealed different host responses to individual pathogens such as TB, bacterial and viral
infections [16,17]. Previous studies of host ‘omics in the context of KD have characterised
the pathways involved in the disease and have established biomarker signatures with
diagnostic potential [18,19]. Interrogating multiple ‘omic datasets in parallel provides more
accurate insights into the molecular dynamics of infection as information captured in one
‘omic layer might not necessarily be captured in another ‘omic layer.
We explored the host transcriptomic and proteomic profiles of children with KD and
those with viral and bacterial infections, aiming to elucidate whether the inflammatory
response in KD is more similar to that of a bacterial or viral infection, or indeed neither.
We also used the approach to explore the heterogeneity within the transcriptional and
translational response of patients with KD.
2. Results
2.1. Description of Datasets
Whole-blood transcriptomic profiles generated from 414 children were included in the
analysis, obtained from children with Kawasaki disease (KD; n = 178), confirmed (definite)
bacterial infection (DB; n = 54), confirmed (definite) viral infection (DV; n = 120), and
healthy controls (HC; n = 62). Two transcriptomic datasets were used. The ‘discovery’
transcriptomic dataset, which was generated by HumanHT-12 version 4.0 BeadChips, was
used for all steps of the analysis. The ‘validation’ transcriptomic dataset, which was created
by merging two datasets generated by HumanHT-12 version 3.0 and 4.0 BeadChips, was
used to test the classifiers trained on the discovery dataset (Table 1).
In addition, proteomic profiles from the plasma or serum of 329 children in the same
groups were studied: from children with KD (n = 52), DB (n = 121) and DV (n = 106)
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infections, and HC (n = 50). Liquid chromatography with tandem mass spectrometry
(LC–MS/MS) and the SomaScan [20] platform were used to generate the proteomic ‘dis-
covery’ and ‘validation’ datasets, respectively (Table 1). The ‘discovery’ proteomic dataset,
generated from plasma samples using LC–MS/MS, was used for all steps of the analysis.
The ‘validation’ proteomic dataset, generated from serum samples using the SomaScan
platform [20], was used to test the classifiers trained on the discovery dataset.
On both ‘omic levels, the datasets that were used as ‘discovery’ datasets were selected
due to their higher number of bacterial and viral samples. There was no overlap between
the patients included in the proteomic datasets and those included in the transcriptomic
datasets.
KD patients were defined according to American Heart Association (AHA) guide-
lines [21]. DB patients had a bacterial pathogen identified in a sample from a sterile site.
DV patients had a virus identified that was consistent with the presenting syndrome; had
no bacteria identified in blood or relevant culture sites; and had C-reactive protein (CRP)
levels <60 mg/L. Further details on the clinical definitions used to define the DV and DB
groups can be found in the Supplementary Text.
The median ages (months) of KD patients in the transcriptomic discovery and validation
datasets were 26 (IQR: 29) and 37 (IQR: 34), respectively. The proportions of male KD patients
were 55% and 60% for the transcriptomic discovery and validation datasets, respectively. For
the proteomic KD group, the median ages (months) were 30 (IQR: 36) and 16 (IQR: 39) for the
discovery and validation datasets, respectively. The proportion of males was 69% for both the
discovery and validation datasets (Tables S1 and S2). Table S2 contains clinical information
for the KD patients included in the four datasets analysed. The causative pathogens for
the patients with bacterial and viral infections from all datasets are shown in Table S3. The
median duration of fever when the blood sample was taken for transcriptomic analysis from
KD patients was 5 (range of 2–7 days) and 6 days (range of 2–10 days) for the discovery and
validation datasets, respectively. For the proteomic KD samples, the median duration of fever
when the sample was taken was 7 (range of 3–20 days) and 6.5 days (range of 4–22 days) for
the discovery and validation dataset, respectively.
Table 1. The datasets used in the analysis. KD, DB, DV and HC are abbreviations for Kawasaki disease, definite bacterial,
definite viral, and healthy control, respectively. LC–MS/MS is an abbreviation for liquid chromatography with tandem
mass spectrometry. * = not used in analysis.
Dataset Name GEOAccession(s) Platform(s) Used for Generation KD DB DV HC Citation(s)
Transcriptomic






1 × HumanHT-12 version 3.0
1 × HumanHT-12 version 4.0
101 23 28 16 * [19,22]
Proteomic
discovery NA LC–MS/MS 26 73 75 25 unpublished
Proteomic
validation NA SomaScan [20] 26 48 31 25 unpublished
2.2. Comparison of Kawasaki Disease to Bacterial and Viral Infection
We explored whether the host response during KD is more similar to the host response
during bacterial or viral infections using transcriptomic (gene-level) and proteomic data.
We first assessed the variance in the discovery datasets using Principal Component Analysis
(PCA; Figure S1 and S2). In the transcriptomic dataset, PC1 (29.24%) appears to be capturing
lymphocyte number and disease group, with the KD patients located between the bacterial
and viral groups. In the proteomic dataset, PC1 (29.18%) appears to be capturing variation
caused by age differences, while PC2 (13.39%) and PC3 (10.56%) strongly capture the
Int. J. Mol. Sci. 2021, 22, 5655 4 of 24
disease group effects, with the KD patients grouped together between the clearly separated
bacterial and viral groups.
2.2.1. Differential Abundance Analysis
Limma [23] was used to identify genes and proteins differentially abundant between
each disease group (KD, DB, DV) and healthy controls (HC), whilst accounting for age, sex
and, for the transcriptomic dataset, immune cell proportions. Features were considered
significantly differentially abundant (SDA) at a FDR of 5%. Differential abundance analysis
was applied to 13,035 genes and 344 proteins. For the transcriptomics, 3213, 3124, and
4663 genes were SDA between KD vs. HC, DB vs. HC, and DV vs. HC, respectively. For
the proteomics, 113, 125, and 78 proteins were SDA between KD vs. HC, DB vs. HC, and
DV vs. HC, respectively. Genes and proteins SDA between KD vs. HC are listed in the
Supplementary File S1.
2.2.2. Pathway Analysis
The lists of SDA features identified in Section 2.2.1 were subjected to pathway analysis
using g:Profiler2 [24] to determine which pathways were upregulated and downregulated
in the three disease groups in the discovery datasets for the transcriptomic (Figure 1a) and
proteomic (Figure 1b) datasets. The full lists of pathways are provided in Supplementary
File S2.
In the transcriptomic pathway analysis, some pathways were found to be enriched
across two or three of the disease conditions, whereas others were found in a single condi-
tion (Figure 1a). For example, neutrophil degranulation, which was the top pathway in
both KD and bacterial infections, and vesicle-mediated transport were both upregulated in
KD and bacterial infections, whereas antigen presentation via MHC class I was upregulated
in KD and viral infections. Of the top 17 pathways enriched in KD, 6 pathways were also
present with concordant directions in the top bacterial pathways and 4 were present with
concordant directions in the top viral pathways. Seven were unique to KD.
In the proteomics data, all pathways overlapping between KD and either bacterial or
viral infections had concordant directions of regulation (Figure 1b). Of the top 19 pathways
enriched in KD, 13 were also enriched in bacterial samples, 10 in viral samples, and 4
were unique to KD. Eight of the top 19 KD pathways were enriched in both bacterial and
viral samples. All of these are involved in the immune response. The higher frequency
of overlapping concordant pathways makes it harder to identify differences between the
pathways enriched in the proteomic dataset than the transcriptomic dataset. Overall, there
was a much lower number of proteins SDA between KD vs. HC (n = 113) than genes
SDA between KD vs. HC (n = 3213). Furthermore, the total number of proteins remaining
following quality control and filtering for missingness (n = 344) was much lower than the
total number of genes remaining following quality control (n = 13,035), which could justify
why the differences in pathways enriched between the disease groups are more apparent
in the gene expression data.
Three pathways were enriched on both ‘omic levels. These were: immune effector pro-
cess pathway (upregulated in KD and bacterial patients); immune response (upregulated
in KD patients); and vesicle-mediated transport (upregulated in KD and bacterial patients).
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Figure 1. (a) Pathways upregulated and downregulated in bacterial, Kawasaki Disease and viral patients compared to healthy controls
in the transcriptomic dataset. (b) Pathways upregulated and downregulated in bacterial, Kawasaki Disease and viral patients compared
to healthy controls in the proteomic dataset.
2.2.3. Clustering
K-Means clustering was used to determine whether the KD patients were more likely
to cluster with bacterial or viral patients in the discovery datasets. Prior to clustering
analysis, gene expression values were corrected for age, sex and immune cell proportions
by taking the residual gene expression values after removing the contributions of these
variables. Immune cell proportions were estimated using CIBERSORTx [25], an online tool
for estimating immune cell proportions from gene expression data. Without correcting the
transcriptomic data for immune cell proportions, clusters formed according to immune
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cell proportion (Figures S3 and S4). The same process was performed to remove the
contribution of age and sex from the protein abundance values. NbClust [26] was used
to determine the optimal number of clusters (k). The value of k most frequently selected
across the 12 indices measured by NbClust was selected as the optimal number of clusters
for downstream analyses. In the transcriptomic analysis, three clusters were identified as
optimal, whereas on the protein level, two clusters were identified as optimal.
We assessed the proportion of KD, bacterial and viral patients in each of the clusters for
the transcriptomic (A) and proteomic (B) datasets (Figure 2). In the transcriptomic analysis,
an over-representation of viral patients was observed in cluster 1 and, to a lesser extent,
cluster 2. An over-representation of bacterial patients was observed in cluster 3 (Figure 2A),
resulting in two viral-like clusters and one bacterial-like cluster. Of the 77 transcriptomic
KD samples, 47 (61%) belonged to cluster 3, 22 (29%) belonged to cluster 2, and 8 (10%)
belonged to cluster 1. In the proteomic analysis, an over-representation of bacterial patients
was found in cluster 1, whereas an over-representation of viral patients was observed
in cluster 2, leading to one viral-like and one bacterial-like cluster (Figure 2A). Of the
26 proteomic KD samples, 24 (92%) belonged to cluster 1 and 2 (8%) belonged to cluster 2.
Figure 2. The proportion of patients from each disease group in each cluster for transcriptomics (A) and proteomics (B). DB,
DV and KD represent definite bacterial, definite viral, and Kawasaki disease.
The association between KD patient cluster membership and various clinical variables
was tested. CRP levels (p-value: 4.8 × 10−2) and lymph node swelling (p-value: 4 × 10−2),
and peeling (p-value: 5 × 10−2) were significantly associated with cluster membership
of KD transcriptomic samples. Higher levels of CRP were found in transcriptomic KD
samples in cluster 3 which had the highest proportion of bacterial samples. Out of the
55 patients displaying peeling, 38 were found in cluster 3, as were 17 of the 21 patients
with lymph node swelling. No clinical variables were associated with cluster membership
in the proteomic dataset. On both ‘omic levels, CRP levels were highest in the clusters in
which the majority of bacterial samples were found (Figures S5 and S6), as expected since a
CRP cut-off of <60 mg/L was required for patients in the DV groups. This pattern was also
observed for the WBC counts in the transcriptomic dataset (Figure S5).
Differential abundance analysis was performed to compare feature abundance in
the KD samples that fell into different clusters. There were 503 genes SDA between
transcriptomic KD samples in cluster 1 vs. clusters 2 and 3, 454 genes SDA between KD
samples in cluster 2 vs. clusters 1 and 3, and 651 genes SDA between KD samples in cluster
3 vs. clusters 1 and 2. These lists of SDA genes were subjected to pathway analysis using
g:Profiler2 [24] to identify pathways upregulated and downregulated within the clusters
(Figure 3). Complete lists of pathways are in Supplementary File S3.
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Figure 3. Pathways upregulated and downregulated in the KD patients in clusters 1, 2 and 3 for the transcriptomic dataset.
Clusters were identified using K-Means applied to KD, DB and DV patients. KD, DB and DV represent Kawasaki Disease,
definite bacterial, and definite viral, respectively. There were 151, 52 and 137 pathways upregulated in clusters 1, 2 and 3,
respectively, and 5, 66 and 137 pathways downregulated in clusters 1, 2 and 3, respectively.
For the transcriptomics, cluster 1 had the highest proportion of viral patients compared
to the other clusters (Figure 2A). The majority of the adenovirus (19/23) and influenza
(16/23) patients were in cluster 1. Cluster 1 KD patients were characterised by upregulation
of anti-viral response pathways, such as interferon and cytokine signalling (Figure 3). In
cluster 2, although the majority of patients were viral, their proportion was not quite as high
as it was in cluster 1 (Figure 2). The majority of the RSV (15/27) patients were in cluster 2.
In the KD patients in cluster 2, various pathways associated with the anti-viral response
were downregulated (Figure 3). Cluster 3 had the highest proportion of bacterial patients
and KD patients (Figure 2). Similarly to cluster 2, the top pathways downregulated for KD
patients in cluster 3 were associated with the anti-viral response, while the inflammatory
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response pathway was strongly upregulated, suggesting that the KD patients in this cluster
were different to those in cluster 1 and that their response was not as viral-like as those in
cluster 1 (Figure 3).
Three pathways—response to biotic stimulus (i.e., a stimulus caused or produced
by a living organism), response to other organism and type I interferon signalling—were
upregulated in viral transcriptomic samples (Figure 1a) and also in the KD samples in the
viral-like cluster 1 (Figure 3). Furthermore, four pathways, including two associated with
interferon signalling, were upregulated in viral transcriptomic samples (Figure 1a) and
downregulated in the KD samples in clusters 2 and 3 (Figure 3). There were five pathways
downregulated in bacterial transcriptomic samples (Figure 1a) and upregulated in KD
transcriptomic samples in cluster 1 (Figure 3), including two related to cytokine signalling.
For the proteomic dataset, two proteins were SDA between clusters 1 and 2: serum
amyloid A1 (SAA1) and retinol binding protein 4 (RBP4). Both of these proteins have
been identified previously as Kawasaki markers, with RBP4 abundance being lower in
active KD [27] and SAA1 being elevated in KD [28]. The two KD patients in cluster 2
displayed the opposite pattern, with higher RBP4 and lower SAA1 abundance than the
other KD patients.
2.2.4. Classification Using Disease Risk Scores
To further assess whether the KD patients elicited more bacterial-like or more viral-like
responses, we built two classifiers that returned the probabilities that a patient is bacterial
or viral through two separate disease risk scores (DRS). A DRS translates the abundance
of features in a discriminatory signature, selected by Lasso [29], into a single value that
can be assigned to each individual [16]. Through using two independent classifiers, the
possibility of a patient being neither bacterial nor viral was allowed. The classifiers were
trained using the ‘omic data that was corrected for age, sex and, for the transcriptomic
dataset, immune cell proportions.
The Lasso model selected 38 genes for the bacterial classifier, of which 26 had in-
creased abundance and 12 had decreased abundance in bacterial patients compared to
viral patients and healthy controls (Table S4). The viral classifier included 32 genes, of
which 13 had increased abundance and 19 had decreased abundance in viral patients
compared to bacterial patients and healthy controls (Table S5). The classifiers trained in
the transcriptomic discovery dataset were tested on bacterial and viral patients from the
transcriptomic validation dataset. The bacterial classifier achieved an area under the ROC
curve (AUC) of 0.935 (95% CI: 0.869–1) and the viral classifier achieved an AUC of 0.935
(95% CI: 0.856–1).
The Lasso model selected 26 proteins for the bacterial classifier, of which 12 had
increased abundance and 14 had decreased abundance in bacterial patients compared to
viral patients and healthy controls (Table S6). The viral classifier included 20 proteins,
of which 11 had increased abundance and 9 had decreased abundance in viral patients
compared to bacterial patients and healthy controls (Table S7). When testing the classifiers
trained in the proteomic discovery dataset on bacterial and viral patients from the validation
dataset, the bacterial classifier achieved an AUC of 0.925 (95% CI: 0.867–0.984) and the viral
classifier achieved an AUC of 0.891 (95% CI: 0.821–0.962). For both ‘omic levels, the 90%
sensitivity of the classifiers in classifying these samples was used to determine the DRS
threshold above which a sample would be classified as bacterial or viral.
The classifiers were applied to KD patients from the discovery and validation datasets
for both ‘omic levels, resulting in bacterial DRS (DB-DRS) and viral DRS (DV-DRS) for
each KD patient (Figures 4 and 5). Classification labels (DB or DV) were assigned to
the KD patients using the DB-DRS and DV-DRS thresholds calculated from applying the
classifiers to the bacterial and viral patients in the validation datasets (Figure S9). Of
the 178 transcriptomic KD samples, 18 (10%) samples had DB-DRS high enough to be
classified as bacterial and 16 (9%) samples had DV-DRS high enough to be classified as
viral. 145 (81%) samples did not achieve DB-DRS nor DV-DRS sufficiently high to lead
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to bacterial or viral classification, and 1 sample was classified as both bacterial and viral
(Figure 4). Of the 52 proteomic KD samples, 40 (78%) achieved DB-DRS high enough to be
classified as bacterial and 18 (35%) achieved DV-DRS high enough to be classified as viral.
10 (19%) proteomic KD samples achieved DB-DRS and DV-DRS high enough for them to
be classified as both bacterial and viral, and 4 (7.7%) were classified as neither (Figure 5).
Figure 4. Bacterial DRS (DB-DRS) plotted against viral DRS (DV-DRS) for KD (discovery and
validation), DB (from the validation cohort) and DV (from the validation cohort) patients from the
transcriptomic datasets. Boxplots are shown for each disease group. KD, DB and DV represent
Kawasaki Disease, definite bacterial, and definite viral, respectively.
To further examine the ‘omic profiles of the KD patients with DB-DRS and DV-DRS
too low for them to be classified as either bacterial or viral, we performed pathway analysis
on the genes or proteins SDA between these KD patients and healthy controls. Amongst
the pathways upregulated on the transcriptomic level, were ‘defence response to fungus’
(p-value: 7 × 10−08) and ‘response to fungus’ (p-value: 7 × 10−07).
The associations of DB-DRS, DV-DRS, bacterial classification as predicted from the
DB-DRS, and viral classification as predicted from the DV-DRS, with various clinical
variables were tested for KD samples from both ‘omic levels. In the transcriptomic KD
samples, clinical measurements of CRP were positively associated with DB-DRS (p-value:
0.002) and bacterial classification (p-value: 0.0001), and negatively associated with DV-DRS
(p-value: 0.002) and viral classification (p-value: 0.023). In the proteomic KD samples,
CRP levels were significantly positively associated with DB-DRS (p-value: 0.013) and
bacterial classification (p-value: 0.007). Peeling was significantly associated with higher
DB-DRS on both ‘omic levels (transcriptomic p-value: 0.041, proteomic p-value: 0.007).
Strawberry tongue was significantly associated with a low score on the transcriptomic
DV-DRS (p-value: 0.045).
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Figure 5. Bacterial DRS (DB-DRS) plotted against viral DRS (DV-DRS) for KD (discovery and
validation), DB (from the validation cohort) and DV (from the validation cohort) patients from the
proteomic datasets. Boxplots are shown for each disease group. KD, DB and DV represent Kawasaki
Disease, definite bacterial, and definite viral, respectively.
For the KD patients from the discovery datasets, the associations between DB-DRS or
DV-DRS and the cluster membership of patients were tested. Transcriptomic KD sample
cluster membership was significantly associated with DB-DRS (p-value: 0.005) and DV-DRS
(p-value: 0.0006), with a stepwise increase in DB-DRS and decrease in DV-DRS from clusters
1 to 3, where cluster 1 was the most viral-like cluster, and cluster 3 was the most bacterial-
like cluster. Proteomic KD sample cluster membership was significantly associated with
DB-DRS (p-value: 0.002) and DV-DRS (p-value: 0.023), with higher DB-DRS and lower
DV-DRS in KD patients in cluster 1, where cluster 1 was the more bacterial-like cluster and
cluster 2 was the more viral-like cluster.
2.3. Clustering of Kawasaki Disease Patients Alone
We performed unsupervised clustering for the KD patients from the discovery datasets
to explore the natural patient stratification formed in the absence of bacterial and viral
comparator patients. For both ‘omic levels, 3 clusters were optimal, as determined by
NbClust [26]. The clusters were identified using the ‘omic data that was corrected for age,
sex and, for the transcriptomic dataset, immune cell proportions. Of the 77 transcriptomic
KD samples, 32 (41%) were in cluster 1 (cluster KD1-T), 23 (30%) were in cluster 2 (cluster
KD2-T), and 22 (29%) were in cluster 3 (cluster KD3-T). Of the 26 proteomic KD samples,
4 (15%) were in cluster 1 (cluster KD1-P), 7 (27%) were in cluster 2 (cluster KD2-P), and
15 (58%) were in cluster 3 (cluster KD3-P).
There was high overlap between the samples in cluster KD1-T and those in the
transcriptomic bacterial-like cluster 3 described in Section 2.2.3 (Figure S10). All except
one of the samples found previously in the transcriptomic viral-like cluster 1 were found
in cluster KD2-T. The majority (n = 14; 64%) of the samples in KD3-T were also found in
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transcriptomic cluster 2. On the proteome level, in Section 2.2.3, all KD samples except two
clustered together in cluster 1. However, the two remaining samples that were previously
in cluster 2 were not assigned to the same cluster.
The association between cluster membership and various clinical variables was tested.
CRP levels were significantly associated with cluster membership for both ‘omic layers
(transcriptomics p-value: 0.041, proteomics p-value: 0.010). Furthermore, coronary artery
aneurysm (CAA) formation was significantly associated with cluster membership in the
proteomic dataset (p-value: 0.020) with 13 of the 21 patients known to not have CAAs being
in cluster KD3-P. On the transcriptomic level, the highest WBC counts and CRP levels were
in cluster KD1-T, and on the proteomic level, WBC counts and CRP levels were highest in
clusters KD2-P and KD1-P, respectively (Figure S7 and Figure S8).
The associations between DB-DRS or DV-DRS and cluster membership of KD patients
when clustered alone was tested. The transcriptomic KD samples’ cluster membership was
significantly associated with DB-DRS (p-value: 0.006) with the highest DB-DRS in cluster
KD1-T. Although the association between transcriptomic KD samples’ cluster membership
and DV-DRS was not significant, the highest DV-DRS values were observed in cluster
KD2-T. There were no significant associations between the proteomic KD samples’ cluster
membership and DB-DRS or DV-DRS.
Differential abundance analysis was performed on the patients that fell into different
clusters. For the transcriptomics, there were 494 genes SDA between cluster KD1-T vs.
clusters KD2-T and KD3-T, 461 genes SDA between cluster KD2-T vs. clusters KD1-T
and KD3-T, and 320 genes SDA between cluster KD3-T vs. clusters KD1-T and KD2-T.
For the proteomics, 42 proteins were SDA between cluster KD1-P vs. clusters KD2-P
and KD3-P, 25 proteins were SDA between cluster KD2-P vs. clusters KD1-P and KD3-P,
and 38 proteins were SDA between cluster KD3-P vs. clusters KD1-P and KD2-P. These
lists of SDA features were subjected to pathway analysis using g:Profiler2 [24] to identify
pathways upregulated and downregulated within the clusters (Figure 6). Complete lists of
pathways are found in Supplementary Files S4–S5.
In the transcriptomic analysis (Figure 6a), cluster KD2-T had features in common
with an anti-viral response, whilst the others did not. Many pathways associated with the
anti-viral response were downregulated in clusters KD1-T and KD3-T, whilst patients in
cluster KD2-T were characterised by the upregulation of viral pathways, including those
associated with cytokine signalling.
The response to biotic stimulus and type I interferon signalling pathways were previ-
ously identified as being upregulated in viral transcriptomic samples (Figure 1a) and in KD
samples in the viral-like cluster 1 when K-Means was applied to KD, DB and DV (Figure 3).
These pathways were downregulated in clusters KD1-T and KD3-T (Figure 6a), indicat-
ing that the transcriptomic response in these samples was less viral-like than samples in
cluster KD2-T.
Four pathways previously identified as being downregulated in bacterial transcrip-
tomic samples (Figure 1a), including two pathways associated with cytokine signalling,
were upregulated in cluster KD2-T. In addition, six pathways upregulated in cluster KD2-
T had already been identified as being upregulated in the viral-like cluster 1 identified
previously (Figure 3). Five pathways of the nine top upregulated pathways in cluster
KD3-T (Figure 6a) were also upregulated in cluster 2 when K-Means was applied to KD,
DB and DV (Figure 3). These were blood coagulation, hydrogen peroxide catabolic process,
antibiotic catabolic processes, hydrogen peroxide metabolic process and regulation of
biological quality.
In the proteomic analysis (Figure 6b), one of the KD clusters had features in common
with the anti-viral response, whilst another KD cluster was more bacterial-like. Amongst
the top pathways enriched in cluster KD1-P and KD2-P were pathways involved in in-
flammation. The top pathways enriched in cluster KD3-P were associated with lipids. Of
the 37 pathways enriched in the proteomic KD samples (Figure 6b), 21 were previously
identified as enriched in proteomic samples (Figure 1b). Of these, six were enriched in
Int. J. Mol. Sci. 2021, 22, 5655 13 of 24
proteomic viral samples (Figure 1b) and samples in cluster KD2-P (Figure 6b) with con-
cordant directions. Furthermore, seven pathways enriched in cluster KD1-P (Figure 6b)
were also enriched in bacterial proteomic samples (Figure 1b) with concordant directions.
These results suggest that cluster KD1-P is a more bacterial-like cluster, whereas cluster
KD2-P is a more viral-like cluster. Some pathways were enriched on both ‘omic levels,
including those associated with blood coagulation, the response to stress and immune
effector processes.
Figure 6. Cont.
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Figure 6. (a) Pathways upregulated and downregulated in transcriptomic KD patients between clusters. Clusters were identified by
K-Means ran on KD patients alone. There were 24, 118 and 24 pathways upregulated in clusters KD1-T, KD2-T and KD3-T, respectively,
and 94, 68 and 75 pathways downregulated in clusters KD1-T, KD2-T and KD3-T, respectively. KD represents Kawasaki Disease.
(b) Pathways upregulated and downregulated in proteomic KD patients between clusters. Clusters were identified by K-Means ran on
KD patients alone. There were 77, 94 and 61 pathways upregulated in clusters KD1-P, KD2-P and KD3-P, respectively, and 64, 104 and
53 pathways downregulated in clusters KD1-P, KD2-P and KD3-P, respectively. KD represents Kawasaki Disease.
3. Discussion
Although the cause of Kawasaki disease has not been identified, there is growing
clinical, epidemiological, and immunological evidence that it may be caused by different
infectious triggers, with data pointing to bacteria, viruses or fungi. We explored the tran-
scriptomes and proteomes of children with KD and definite bacterial and viral infections,
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using multiple approaches to compare the host response to these diseases to the response
during KD. We found that there was a diversity of responses in the proteomic and tran-
scriptomic profiles of KD patients, suggesting that KD is not a homogenous condition,
and that whilst some patients had a more viral- or bacterial-like profile, the majority were
defined as neither bacterial nor viral when their transcriptomic response was mapped onto
viral and bacterial disease risk scores (DRS).
Within the host response profiles, some elements of KD appeared more viral-like and
some elements appeared more bacterial-like. This is shown through overlapping pathways
that were enriched in KD and either bacterial or viral infections. For example, the antigen
presentation via MHC class I pathway was upregulated in KD and viral infections on the
transcriptomic level. Major histocompatibility complex (MHC) molecules are expressed on
the cell surface to present antigenic peptides to T cells, and their expression is increased by a
broad range of immune activators including interferons [30,31]. The finding of upregulated
MHC class I expression in KD and viral patients may reflect interferon-induced activation
in these groups. Additionally, on the transcriptomic level, KD and bacterial infections
share neutrophil degranulation as their most upregulated pathway. Neutrophils are the
first responders to infection and inflammation, and the expansion and activation of the
neutrophil population is a characteristic feature of acute KD. In the initial days of KD
illness, there is an intense inflammatory response with neutrophil leucocytosis [32]. Studies
have found elevated levels of human neutrophil elastase and IL-8, a C-X-C chemokine that
activates neutrophils [33,34].
The host response during KD is highly heterogenous, as demonstrated through the
enrichment of certain pathways in the KD patients in different clusters when K-Means
was applied to KD, bacterial and viral transcriptomic samples. For example, anti-viral
response pathways were upregulated in KD patients in the majority viral cluster 1 and
downregulated in KD patients in clusters with decreasing numbers of viral samples (cluster
2, 3), relative to each other. In the majority bacterial cluster 3, pathways associated with
the inflammatory response were upregulated. The heterogeneity of the host response
during KD was also apparent when K-Means was applied to KD patients alone. Three
distinct clusters were identified on both ‘omic levels, and, in each cluster, a distinct set of
pathways was enriched. The range of pathways enriched in the different clusters further
demonstrate the heterogeneity in the host response during KD, with some clusters enriched
for viral response pathways and some clusters enriched for bacterial response pathways.
Unsurprisingly, amongst the patients clustering in the more bacterial-like clusters, their
DB-DRS tended to be higher, and amongst the patients clustering in the more viral-like
clusters, their DV-DRS tended to be higher.
The two different approaches to clustering (with and without bacterial and viral
comparator samples) produced similar clusters of KD patients, providing reassurance that
the clusters described here are biologically meaningful. Despite the similarities, however,
the clusters identified in Sections 2.2.3 and 2.3 were not completely identical, indicating
that the inclusion of well-characterised bacterial and viral patients adds further insights to
the solely data-driven KD-based analysis.
Although there are shared features between the response to KD and both bacterial
and viral infections, the distinct pathways enriched in each disease group demonstrate
the variation in the molecular host response; the distinctiveness of the responses is also
supported by the ability of RNA and protein signatures to discriminate KD from bacterial
and viral infections [18,19,35]. These differences between the response during KD and the
responses to bacterial and viral infections suggest that KD may be triggered by a novel
process not typical of either common bacterial or viral infections. Despite the host ‘omics
profiles’ heterogeneity observed in KD, commonalities are also shown.
A two-way classifier approach highlighted that it is not a simple dichotomous question
as to whether the response during KD more closely resembles the responses to bacterial
or viral infections, when focusing on key discriminatory features. We found that 145 of
the 178 transcriptomic KD samples were not assigned DRS high enough for them to be
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classified as either bacterial or viral, and amongst pathways upregulated in these KD
patients compared to healthy controls were two pathways associated with the fungal
response. This finding is intriguing, given the evidence suggesting that KD could be caused
by a fungal trigger that has been reported elsewhere [36,37].
The heterogeneity and the different clusters of responses to KD which have elements
shared with bacterial, viral or fungal responses, could indicate multiple microbial triggers
of KD, as has been suggested by Rypdal et al. [11]. An alternative explanation for the
heterogeneity observed here in the response during KD could be that a single pathogen
that causes KD leads to heterogeneous responses in different hosts, as has been observed
in children infected with SARS-CoV-2, where many children remain asymptomatic, some
experience severe inflammation [38,39], and some develop PIMS-TS/MIS-C [13,14,40].
Variations in the host condition, such as epigenetic differences and differences in prior
pathogen exposure, could cause the spectrum of host responses to KD observed here.
Differences in host genetics could also be responsible for the heterogeneity in host response
during KD as the severity of KD, including the formation of CAAs, is already known to be
impacted by the host’s genetic background [41].
This study has certain limitations. The proteomic discovery dataset was a lower-
dimensional dataset (n = 867) than the transcriptomic discovery dataset (n = 47,323) with
high rates of missingness, as is common in quantitative proteomics. Only proteins with no
missingness were used for the clustering and classification, so key proteins for distinguish-
ing KD could be absent from the analysis. On the proteomic level, many pathways were
enriched in multiple disease groups (Figure 1b), making it difficult to identify a disease-
specific pathway signature. This could be caused by plasma samples, which were used in
this dataset, capturing a noisy signal due to the release of substances from various tissues
into the bloodstream. The proteomic response during KD shared more similarities with
the proteomic response to bacterial infection, with more pathways overlapping between
KD and bacterial infections (Figure 1b) and all but two KD proteomic samples clustering
with bacterial proteomic samples (Figure 2). This follows observations of striking clinical
similarities between KD and bacterial streptococcal and staphylococcal toxic shock syn-
dromes [42,43], and could reflect the hypothesis that the proteome is closer to the observed
phenotype than the transcriptome [44].
Although bacterial patients with known viral coinfections have been removed from
the analysis, it is impossible to say with confidence that an individual does not have a
coinfection, the presence of which could falsely increase heterogeneity in the host response
in a given disease group. Coinfection is common in KD, with one study identifying
confirmed infections in a third of KD patients [45]. Despite being unable to rule-out that
some KD patients included had co-incident viral or bacterial infections, we found that
most KD transcriptomic samples were neither classified as viral nor bacterial when the
respective DRS scores were applied. Amongst the patients classified as bacterial or viral, it
is possible that some patients could be suffering from an intercurrent infection in addition
to KD.
There are variations in the range of bacterial and viral pathogens and the severity of
illness represented in the two ‘omic datasets. The bacterial and viral patients included
in the transcriptomic datasets and the proteomic validation dataset were more severely
unwell than those included in the proteomic discovery dataset (Table S3) due to the
inclusion criteria of the studies to which they were recruited. The KD patients included
in the transcriptomic dataset were collected from San Diego, CA, USA, whereas the KD
patients included in the proteomic dataset were collected from London, UK, although
the same case definition was used. There remains no diagnostic test for KD, thus some
KD patients presented here may have unrecognised alternative diagnoses. The two KD
samples in the proteomic dataset that cluster separately (Figure 2B) and are distinguished
from the other KD samples by their levels of SAA1 and RBP4, two previously identified
KD markers [27,28], are possible examples of this.
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4. Materials and Methods
4.1. Patient Recruitment
All samples were obtained from patients with written parental informed consent. Case
definitions can be found in the Supplementary Text. The definite bacterial (DB), definite viral
(DV), healthy control (HC) and Kawasaki disease (KD) samples used in the transcriptomic
discovery and validation datasets were recruited in the United Kingdom and Spain as part of
the IRIS (Immunopathology of Respiratory, Inflammatory and Infectious Disease; NIHR ID
8209) and GENDRES (Genetic, Vitamin D, and Respiratory Infections Research Network; gen-
dres.org) studies [17,22] and in the United States through the US-Based Kawasaki Disease Re-
search Center Program (medschool.ucsd.edu/som/pediatrics/research/centers/kawasaki-
disease/pages/default.aspx).
The DB, DV and HC samples used in the proteomic discovery and validation datasets
were enrolled in the EUCLIDS (European Union Childhood Life-Threatening Infectious
Disease Study; 11/LO/1982) study [46] and the PERFORM (Personalised Risk assessment
in Febrile illness to Optimise Real-life Management across the European Union) study (per-
form2020.org/; 16/LO/1684). KD samples used in the proteomic datasets were recruited
from the ongoing UK Kawasaki study “Genetic determinants of Kawasaki Disease for
susceptibility and outcome” (13/LO/0026). This study recruits acutely unwell children
with KD during hospital admission in participating hospitals around the UK.
4.2. Data Generation
4.2.1. Transcriptomic Datasets
The transcriptomic discovery dataset was generated from whole-blood samples ob-
tained from KD patients, healthy controls, and patients with bacterial and viral infections
using the HumanHT-12 version 4.0 (Illumina, San Diego, CA, USA) microarray [18]. In
order to obtain a transcriptomic validation dataset containing the same disease groups as
the transcriptomic discovery dataset, two datasets were merged. One dataset contained
gene expression values (HumanHT-12 version 4.0 [Illumina, San Diego, CA, USA] microar-
ray) from whole-blood samples obtained from acute and convalescent KD samples [19].
The other dataset consisted of gene expression values (HumanHT-12 version 3.0 [Illumina,
San Diego, CA, USA] microarray) from whole-blood samples obtained from patients with
bacterial and viral infections [22]. For all three independent microarray experiments, one
batch of samples was processed, and samples were randomly positioned across the arrays.
4.2.2. Proteomic Datasets
The proteomic discovery dataset was generated from plasma samples using LC–
MS/MS. Full details of the experimental protocol are in the Supplementary Text. The
proteomic validation dataset was generated from serum samples using the SomaScan
(SomoLogic, Boulder, CO, USA) aptamer-based platform [20]. Prior to pre-processing,
867 proteins were measured in the discovery dataset (LC–MS/MS) and 1300 in the vali-
dation dataset (SomaScan). Samples in the proteomic validation dataset were split across
three plates with KD, DB, DV and HC samples present on each plate in relative proportions.
4.3. Statistical Methods
All analysis was conducted using the statistical software R (R version 3.6.1, [47]).
Code used for the analytical pipeline described here is found at github.com/heather-
jackson/KawasakiDisease_IJMS. Note, the code is signposted for the transcriptomic datasets
but can be modified for other ‘omic levels.
4.3.1. Pre-Processing of Gene Expression Data
Background correction, robust spline normalisation (RSN), and log2 transformation
were applied to the raw discovery gene expression dataset using the R package lumi [48].
Probes were retained if at least 80% of samples in each comparator group had a detection
p-value < 0.01. Low variance probes and those significantly associated with the UCSD
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recruitment site were removed. Bacterial samples with known viral coinfections were
removed from the analysis at this stage to ensure that the signal from the bacterial samples
was not diluted. KD samples that had been administered IVIG treatment were also removed
at this stage, but their inclusion was irrespective of coincident viral or bacterial detection,
for which data was not available. A KD sample previously identified as an outlier [18]
was removed.
As mentioned, two microarray gene expression datasets were merged to form the
validation dataset. Background subtraction and RSN normalisation were applied to these
two datasets independently, using the R package lumi [48], prior to using ComBat [49] to
remove the batch effects in the merged dataset [18].
4.3.2. Pre-Processing of Protein Abundance Data
The raw discovery dataset files generated by LC–MS/MS were processed using
MaxQuant (1.6.10.43) [50]. With matching between runs activated. Relative quantification
was performed using the MaxLFQ algorithm [51]. The resulting LFQ values were log2-
transformed. Bacterial samples with known viral coinfections were removed from the
analysis at this stage to ensure that the signal from the bacterial samples was not diluted.
Protein groups were removed if they were identified as contaminants, or if they were
missing in over 90% of samples in each disease group.
The proteomic validation dataset was generated from the SomaScan platform [20].
Quality control steps used scale factors returned from the SomaScan platform to correct for
variations in aptamer hybridisation efficiency, inter- and intra-assay variability, variability
in the starting quantities of proteins, and plate effects. Further batch effect corrections were
carried out using COCONUT normalisation [52].
4.3.3. Comparison of Kawasaki Disease to Bacterial and Viral Infections
Differential Abundance Analysis
Differential abundance analysis was carried out to compare the overall transcriptomic
and proteomic responses to KD, definite bacterial (DB) and definite viral (DV) infections.
The degree to which genes and proteins were differentially abundant between KD and
healthy controls (HC), DB and HC, and DV and HC was quantified using Limma [23]
on the transcriptomic and proteomic discovery datasets separately. Age and sex were
included as covariates for both datasets. Immune cell proportions, calculated using the
online CIBERSORTx portal [25], were used as additional covariates for the transcriptomic
dataset. The immune cell proportions included were lymphocytes, neutrophils, monocytes,
mast cells and eosinophils. Features were considered significantly differentially abundant
(SDA) at a false discovery rate (FDR) [53] of 5%.
Pathway Analysis
The pathways upregulated and downregulated in KD, DB, and DV samples were
identified from the lists of SDA features identified for each disease group in as outlined in
Section Differential Abundance Analysis. Pathways were identified using g:Profiler2 [24]
and redundancy in the pathways identified was removed using REVIGO [54].
Clustering Analysis
K-Means clustering [55] was applied separately to transcriptomic and proteomic
discovery datasets. Healthy controls were excluded as we were only interested in the
clustering of KD with pathological patients. For the proteomic dataset, only proteins with
no missing data points were used (n = 106).
To explore the effects of sex and age on clustering in the proteomic dataset, the
contribution of these variables was removed by regressing out their effects on every protein
and taking the residual values as the ‘corrected’ abundance. This process was also followed
in the transcriptomic dataset, but the contributions of the immune cell proportions listed
in Section Differential Abundance Analysis were also removed. Prior to clustering, and
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after correction, features were removed if their variance was lower than 0.25. To determine
the optimal number of clusters (k) for each corrected and non-corrected dataset, the R
package NbClust [26] was used, with 12 indices tested. The indices tested were: KL [56],
CH [57], Hartigan [58], McClain [59], Dunn [60], SDIndex [61], SDbw [62], C-Index [63],
Silhouette [64], Ball [65], Ptbiserial [66,67] and Ratkowsky [68]. The number of clusters
tested by NbClust ranged between 2 and 10 clusters. The most frequently selected k by the
12 indices was used for downstream analyses. The lowest k selected the most frequently
was taken in cases where there were multiple values of k selected the most frequently.
Once clusters were identified, features that were SDA (5% FDR) between KD samples
in the different clusters were identified. Pathway analysis was done using these lists of
SDA features to determine the pathways upregulated and downregulated in KD samples
in the different clusters. The R package g:Profiler2 [24] was used for pathway analysis,
with pathways with p-values < 0.01 considered significant. Redundancy in the pathways
identified was removed using REVIGO [54].
The associations between cluster membership and various clinical variables were
tested. For categorical variables, Fisher’s Exact test was used. For continuous variables,
one-way ANOVA was used. p-values < 0.05 were considered significant. The categorical
variables tested in both datasets were: strawberry tongue (yes/no/unknown); lymph
node swelling (yes/no/unknown); and peeling (yes/no). Continuous variables tested in
both datasets were: levels of C-reactive protein (CRP); month of year; and the duration of
fever at sampling. Coronary artery aneurysms (CAA) information was available only as a
dichotomous variable for the patients submitted for proteomic analysis. For the patients
submitted for transcriptomic analysis, maximal coronary artery Z-scores were available
and were used instead.
Classification
Two independent classifiers were built for each ‘omic dataset. One classifier was for
classifying DB patients (DB classifier), and the other was for classifying DV patients (DV
classifier). The DB classifiers and DV classifiers were trained on features SDA between DB
vs. DV and HC patients combined, and DV vs. DB and HC patients combined, respectively.
Only features present in both datasets (discovery and validation) were used for training the
classifiers. The discovery datasets that were corrected for age, sex, and for transcriptomics,
immune cell proportions, were used to train the classifiers. The validation datasets were
also corrected for age, sex and, for the transcriptomic validation dataset, immune cell
proportions as determined by CIBERSORTx [25]. The proteomic discovery and validation
datasets were generated using different platforms. Therefore, each dataset was scaled so
that all abundance values were between 0 and 1, and then the two datasets were quantile
normalised together. Proteins with no missing values that were also found in the proteomic
validation dataset were used to train the proteomic classifier.
The DB classifiers were trained to identify DB patients from DV and HC patients,
whereas the DV classifiers were trained to identify DV patients from DB and HC patients.
Lasso regularised regression [29] was used to identify the discriminatory features and their
weights for each classifier. For each sample, a disease risk score (DRS) was calculated using
the abundance of the features selected by Lasso, as described by Kaforou et al. in [16]. The
DRS was calculated by totalling the abundance of features with positive Lasso weights and
subtracting from this total the abundance of features with negative Lasso weights. Features
were only included in the DRS if their Lasso weight direction and log-fold change direction
were concordant. DRS were scaled between 0 and 1.
The classifiers were tested on the DB and DV patients of their respective validation
dataset. The cut-off threshold above which a sample was classified as DB or DV was
calculated using the coords function in the R package pROC [69] using a sensitivity cut-
off of 90%. The classifiers were then tested on the KD patients from the discovery and
validation datasets and the thresholds identified by pROC were used to determine if the
KD patients were classified as DB or DV. If patients were classified as neither bacterial nor
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viral according to their DRS, differential abundance analysis followed by pathway analysis
(as described in Section Pathway Analysis) was done to identify the pathways enriched in
these patients compared to healthy controls.
4.3.4. Exploration of Kawasaki Disease Samples Alone
In order to identify the natural clusters formed by KD patients in the absence of
bacterial or viral patients, K-Means clustering was done separately on the KD patients. The
process followed was the same as outlined in Section Clustering Analysis. The association
between cluster membership and clinical variables was tested. The clinical variables and
the statistical tests used were the same as outlined in Section Clustering Analysis.
5. Conclusions
Taken together, the results from differential abundance analysis, pathway analysis,
clustering and classification suggest that the host transcriptomic and proteomic responses
during KD are highly heterogenous. Different clusters of host responses during KD
were identified, some of which resemble elements of host responses to bacterial, viral
and fungal infections. These differences in the host responses could imply that KD is
triggered either by several different pathogens, or by a single pathogen that has different
manifestations according to the underlying genetic and environmental situation of the
host. Whilst there are similarities between the host response during KD and the host
response to bacterial infections and viral infections, there are also many differences in the
responses, suggesting that KD may be triggered by a novel process not typical of either
common bacterial or viral infections. This was demonstrated by the majority of the KD
transcriptomic samples falling into a non-bacterial, non-viral group following classification,
raising the possibility that the minority of KD transcriptomic samples with bacterial or
viral profiles were possibly suffering from intercurrent infection in addition to a separate
KD trigger. Our data further suggests that research into the aetiologies of KD should be
focused on cohorts of KD patients who share similar clinical characteristics in order to
identify shared molecular responses.
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